GlassScriptPhysician profile
Casandra A Anderson
NPI 1083773170
$403.83
in general payments reported to CMS, 2019-2025
11 companies · $82.27 in 2025
The $82.27 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $68.00 · 2021: $72.50 · 2022: $87.62 · 2023: $65.84 · 2024: $27.60 · 2025: $82.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $104.26 | 2021-2023 | Trodelvy |
| Amgen INC. | $68.00 | 2020 | |
| Springworks Therapeutics, INC. | $54.60 | 2025 | Ogsiveo |
| Beigene USA, INC. | $28.53 | 2021 | |
| Spectrum Pharmaceuticals INC. | $27.67 | 2025 | Rolvedon |
| Daiichi Sankyo INC. | $27.60 | 2024 | Enhertu |
| Digestive Care, INC. | $24.79 | 2023 | Pertzye |
| Ipsen Biopharmaceuticals, INC | $22.56 | 2023 | Tazverik |
| Acrotech Biopharma INC. | $15.88 | 2021 | |
| Tactile Systems Technology INC | $15.68 | 2022 | |
| Deciphera Pharmaceuticals INC. | $14.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Casandra Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.